Champions for safety-net health care providers on one side and drug manufacturers and oncologists in private practice on the other faced off yesterday during a health care news service’s webinar on the 340B program.
Blog Posts
Hospitals in the 340B program and oncologists working in private practice have issued dueling reports about who profits unjustly in connection with the drug discount program.
Please Login or Become a Paid Subscriber to View this
A federal district judge in Washington, D.C., yesterday scheduled an Oct. 12 joint hearing on pending motions in drug manufacturers’ Novartis and United Therapeutics’ 340B contract pharmacy lawsuits.
Please Login or Become a Paid Subscriber to
Sanofi Reaches Out to 340B Entities that Complained to HRSA About its Contract Pharmacy Restrictions
Drug manufacturer Sanofi has sent letters to 340B covered entities that have complained to federal authorities about its denials of 340B pricing on drugs shipped to contract pharmacies, covered entity representatives say.
Please Login or Become
The dumping of a controversial Trump administration rule limiting what 340B health centers can charge patients for insulin and EpiPen-type devices took a big step closer to being finalized last week.
Please Login or Become a
SPONSORED CONTENT
An HIV diagnosis does not have the same meaning today as when the virus first emerged in the 1980s. People living with HIV can now expect to live a long, full life, as long as they adhere to a prescribed antiretroviral treatment regimen. AIDS Healthcare Foundation (AHF), the largest provider of HIV/AIDS medical care globally, plays a key
…
An Arkansas Insurance Department hearing officer said last week she would decide by Oct. 13 whether to stay enforcement of a state law requiring drug manufacturers to honor 340B contract pharmacy arrangements pending resolution of a bevy of federal lawsuits
…
Nine friend-of-the-court briefs have been filed in the nation’s highest court urging rejection of an appeals court’s decision last year that upheld a huge cut in 340B hospitals’ Medicare reimbursement for physician administered drugs.
Please Login
Napo Pharmaceuticals yesterday posted a public notice to 340B covered entities about how to obtain 340B pricing on Mytesi, an antidiarrheal for patients living with HIV/AIDS who take antiretroviral drugs.
Please Login or Become a Paid
SPONSORED CONTENT
It is my pleasure to introduce our company to 340B Report’s readers. RxPreferred Benefits is a fully transparent 340B Administrator and Pharmacy Benefit Manager (PBM) founded, and solely owned, by independent pharmacy representatives. Privately held and headquartered in Nashville, TN, RxPreferred operates nationally, partnering with a wide range of clients including: 340B covered entities, self-funded employers, hospitals, health systems, hospices, pharmacies, brokers, and third-party administrators.
Zero Conflicts-of-Interest
…